Raj K. Puri - Nov 22, 2024 Form 3 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role
Chief Regulatory Officer
Signature
/s/ Raj K. Puri
Stock symbol
IOVA
Transactions as of
Nov 22, 2024
Transactions value $
$0
Form type
3
Date filed
12/2/2024, 05:25 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IOVA Common Stock 151K Nov 22, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IOVA Stock Options (Right to Buy) Nov 22, 2024 Common Stock 325K $12.38 Direct F2
holding IOVA Stock Options (Right to Buy) Nov 22, 2024 Common Stock 35.9K $7.12 Direct F2
holding IOVA Stock Options (Right to Buy) Nov 22, 2024 Common Stock 57.9K $7.12 Direct F2
holding IOVA Restricted Stock Units Nov 22, 2024 Common Stock 120K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 3,472 shares of the Issuer's common stock purchased under the Issuer's 2020 Employee Stock Purchase Plan.
F2 Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.
F3 The remaining restricted stock units ("RSUs") will vest in equal quarterly installments.
F4 Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Remarks:

1. On November 22, 2024, Raj K. Puri was promoted to Chief Regulatory Officer from his previous position as Executive Vice President, Regulatory Strategy and Translational Medicine. Dr. Puri joined Iovance Biotherapeutics, Inc. (the "Issuer") in March 2022.